Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 26, 2005

Primary Completion Date

January 1, 2010

Study Completion Date

March 31, 2017

Conditions
Intraocular Retinoblastoma
Interventions
DRUG

Carboplatin

Given IV

PROCEDURE

Cryosurgery

PROCEDURE

Infrared Laser Therapy

RADIATION

Iodine I-125

Undergo radioactive therapy

RADIATION

Radiation Therapy

Undergo radioactive therapy

RADIATION

Ruthenium Ru-106

Undergo radioactive therapy

DRUG

Vincristine Sulfate

Given IV

Trial Locations (10)

19104

Children's Hospital of Philadelphia, Philadelphia

Children's Oncology Group, Philadelphia

27710

Duke University Medical Center, Durham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48201

Wayne State University/Karmanos Cancer Institute, Detroit

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

90027

Children's Hospital Los Angeles, Los Angeles

98109

Fred Hutchinson Cancer Research Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00079417 - Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma | Biotech Hunter | Biotech Hunter